U.S. Healthcare Services Stock News

Gartner (IT) has put fresh numbers on the board for Q1 2026, reporting revenue of US$1.5b and basic EPS of US$3.19 off net income of US$222.3m, setting the tone for how you might think about the rest of the year. Over recent quarters the company has seen revenue move between US$1.5b and US$1.8b, while quarterly EPS has ranged from US$0.47 to US$5.14, providing a clear view of how earnings power has fluctuated into this latest print. With trailing net margins now sitting well below last year’s...

If you are wondering whether NuScale Power's current share price reflects its true worth, this article will help you size up the stock using several valuation tools. The stock recently closed at US$11.87, with returns of 0.4% over 7 days, 16.9% over 30 days, a 27.2% decline year to date, a 32.8% decline over 1 year, 47.6% over 3 years and 19.8% over 5 years. This gives you a wide range of outcomes to think about. Recent coverage has focused on NuScale Power's role in nuclear energy...

Alkermes Q1 2026 earnings: setting the stage Alkermes (ALKS) heads into Q1 2026 following its Q4 2025 report, where revenue was US$384.5 million and basic EPS came in at US$0.30, with net income excluding extra items of US$49.3 million. Over recent quarters, the company has reported revenue of US$429.99 million in Q4 2024, US$390.7 million in Q2 2025, and US$394.2 million in Q3 2025. Quarterly basic EPS over that period was US$0.90 in Q4 2024, US$0.50 in Q3 2025, and US$0.30 in Q4 2025. These...

Revvity Q1 2026 earnings snapshot Revvity (RVTY) has just put fresh numbers on the table, with recent quarters showing revenue between US$664.8 million and US$772.1 million and basic EPS ranging from US$0.35 to US$0.85 as the company heads into its Q1 2026 update. Over the past year, revenue has been recorded from US$684.0 million in Q3 2024 up to US$772.1 million in Q4 2025, while basic EPS prints in that stretch run from US$0.35 to US$0.85, giving investors a clear view of how the top line...

Wondering if Ally Financial at around US$43 per share still offers value, or if most of the easy gains are behind it, starts with understanding what the current price is actually reflecting. The stock has had mixed recent returns, with a 2.7% decline over the last week, an 8.5% gain over the last month, a 5.6% decline year to date, and a 36.8% return over the last year alongside an 88.9% three year return and a 2.9% five year decline. Recent coverage has focused on how Ally Financial fits...

Avista’s Q1 2026 earnings in focus Avista (AVA) has rolled into Q1 2026 on the back of a solid run through 2025, capped by Q4 revenue of US$533 million and basic EPS of US$0.87, alongside trailing 12 month EPS of US$2.38 on US$1.96 billion of revenue. Over recent quarters, the company has seen revenue hold in a US$394 million to US$617 million range while quarterly EPS moved between US$0.17 and US$0.98. The trailing net profit margin is 9.8% compared with 9.3% a year earlier, which puts the...

AGCO (AGCO) has just opened Q1 2026 earnings season with recent quarterly numbers that plot a sharp swing in profitability, moving from a Q4 2024 net loss of US$255.7 million on US$2,887.3 million of revenue and EPS of US$3.43 loss, to Q4 2025 net income of US$95.5 million on US$2,920.2 million of revenue and EPS of US$1.29. Over the same period, trailing twelve month EPS shifted from a US$5.69 loss on US$11.7 billion of revenue to US$9.76 on US$10.1 billion. Revenue moved from US$2,599.3...

Investors may be wondering if ConocoPhillips at around US$123.32 still offers value after a strong run, or if recent enthusiasm has already been priced in. The stock has seen a 27.5% return year to date and 45.5% over the last year, even though the last 7 days and 30 days showed returns of a 0.8% decline and a 5.5% decline, respectively. Recent coverage has focused on ConocoPhillips as a major integrated energy producer, with attention on how it is positioning its portfolio and capital...

AnaptysBio recently reported that the Delaware Chancery Court dismissed Tesaro’s anticipatory breach of contract claim over their Jemperli collaboration, while CEO Daniel Faga is set to discuss the company’s royalty assets at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on May 6, 2026. This legal outcome, combined with a stronger earnings outlook highlighted by an upgraded Zacks rank, strengthens AnaptysBio’s position around its Jemperli-related royalty rights. We’ll now...

AGNC Investment (AGNC) opened 2026 with a softer quarter, reporting Q1 total revenue of a loss of US$114 million and a basic EPS loss of US$0.17, set against trailing twelve month revenue of US$1.6 billion and EPS of US$1.22. Over recent periods the company has seen quarterly revenue move from US$154 million in Q4 2024 to US$995 million in Q4 2025, with basic EPS shifting from US$0.10 to US$0.83 over the same span. Trailing twelve month revenue rose from US$973 million in Q4 2024 to US$1.8...

Wondering whether Scotts Miracle-Gro at around US$60.06 is priced for a recovery or still carrying too much risk? This article focuses on what the current share price might be implying about value. The stock has been volatile recently, with a 7 day return of an 8.1% decline, a 30 day return of a 6.0% decline, and a 1 year return of 14.3%, while the 5 year return sits at a 70.3% decline. Recent headlines around Scotts Miracle-Gro have focused on the company’s position in consumer lawn and...

Elevance Health (NYSE:ELV) is rolling out nationwide mental health access and early intervention programs through community partnerships and digital tools. The Elevance Health Foundation currently has $23 million in active grants focused on mental health initiatives across the United States. These efforts aim to connect members with earlier, community-based care that complements the company’s existing clinical programs. For investors watching NYSE:ELV, this push into broader mental health...

This article examines whether Cohen & Steers at US$69.54 is offering fair value and breaks down what the current price may be indicating about the stock. The share price is up 0.9% over the last week and 11.0% over the past month. Year to date it is up 9.4%, while the 1 year return stands at a 6.4% decline, set against a 3 year return of 42.2% and a 5 year return of 17.1%. Recent headlines have focused on Cohen & Steers in the context of the wider Capital Markets sector, with attention on...

IAC (IAC) has just posted its Q1 2026 scorecard, and the latest trailing twelve month figures show total revenue of about US$2.4 billion with a basic EPS loss of US$1.49 and net income excluding extra items of US$119.31 million in losses. Over recent quarters the company has seen quarterly revenue move from US$642 million in Q3 2024 to US$721.44 million in Q4 2024, then to US$570.49 million in Q1 2025 and US$645.98 million in Q4 2025. Basic EPS shifted from a loss of US$3.40 in Q3 2024 to a...

Viper Energy Q1 2026 earnings snapshot Viper Energy (VNOM) opened Q1 2026 with mixed signals, as trailing twelve month revenue sat at US$1.3 billion against a loss of US$69 million, translating into trailing EPS of US$0.48. The most recent quarterly print in Q4 2025 showed revenue of US$411 million and a net loss of US$103 million, or EPS of US$0.61. Over the past few reported quarters, revenue has moved from US$232 million in Q1 2025 to US$283 million in Q2 2025, US$399 million in Q3 2025...

Investors may be wondering whether Oppenheimer Holdings at around US$99 a share still offers value, or if most of the opportunity has already been priced in. The stock has been volatile recently, with an 11.3% pullback over the last 7 days alongside a 9.3% gain over 30 days, and returns of 36.8% year to date and 69.4% over the past year. Recent headlines around capital markets activity and trading conditions have kept investor attention on brokers and financial services stocks, including...

If you are wondering whether Weatherford International at around US$108.61 is still offering value after its run, this breakdown will help you see what the current price really reflects. The stock has seen a 14.0% gain over the last 30 days and a 34.3% return year to date, while the 1 year return sits at 151.7% despite a 1.5% decline over the past week. Recent news around Weatherford International has focused on its position within the broader energy services sector and how investors are...

XCF Global (SAFX) has drawn fresh attention after a series of updates, including a Q1 2026 operational briefing, a business combination agreement, a forbearance deal with lender Twain, and a sector conference appearance. See our latest analysis for XCF Global. Recent updates around the Reno facility restart, the business combination agreement, and the Twain forbearance deal have coincided with a sharp shift in sentiment, with a 90 day share price return of 166.1% but a 3 year total...

The market for SuperCom Ltd.'s ( NASDAQ:SPCB ) stock was strong after it released a healthy earnings report last week...

Readers hoping to buy Lazard, Inc. ( NYSE:LAZ ) for its dividend will need to make their move shortly, as the stock is...

Q1 2026 earnings snapshot sets up margins story for Travere Therapeutics (TVTX) Travere Therapeutics (TVTX) heads into its Q1 2026 update with recent quarterly revenue of US$129.7 million in Q4 2025 and basic EPS of US$0.29 in Q3 2025 giving way to a loss of US$0.24 per share in Q4, alongside trailing 12 month revenue of US$490.7 million and a net loss of US$50.3 million. Over the past year, revenue has moved from US$233.2 million on a trailing 12 month basis in Q4 2024 to US$490.7 million in...

Spectrum Brands Holdings (NYSE:SPB) has entered into a partnership with Oaktree Capital Management focused on its Home and Personal Care business. The transaction brings new investment into the segment and marks another step in Spectrum Brands' plan to separate this business from the rest of the company. The move is intended to reshape how Spectrum Brands allocates resources across its portfolio and could influence how investors view the stock. At a share price of $82.38 and with a return...

We wouldn't blame Viavi Solutions Inc. ( NASDAQ:VIAV ) shareholders if they were a little worried about the fact that...

Chiesi Farmaceutici S.p.A. has entered into a definitive agreement to acquire KalVista Pharmaceuticals (NasdaqGM:KALV). The deal includes a tender offer followed by a merger process, with completion subject to specified closing conditions. Responsibility for EKTERLY®, a treatment for hereditary angioedema (HAE), is set to move from KalVista to Chiesi once the transaction is finalized. KalVista focuses on treatments for hereditary angioedema, and EKTERLY® is a key product in that portfolio...